Moderna Stock Sees Massive Surge as Short Sellers Get Squeezed

Moderna recently saw a dramatic 177 percent jump in its stock price. This move was triggered by a combination of new positive clinical trial data and a massive short squeeze. While the company only saw a relatively small adjustment to its long term sales estimates, the sudden change in sentiment forced short sellers to scramble to cover their positions, leading to nearly 5 billion dollars in losses for those betting against the stock.

Following the spike, major financial institutions like Bank of America and Morgan Stanley have issued new, higher price targets. Analysts are particularly interested in the company potential to diversify beyond infectious disease vaccines. However, the initial momentum has already begun to cool as profit takers move in and the intensity of the short squeeze fades.

Investors are now looking toward the ESMO Congress in Madrid this October. This event is expected to feature the release of detailed clinical data from the latest trial. Until then, experts suggest the stock will likely experience significant volatility as the market waits for more concrete evidence regarding the true impact of the new drug results.

Most analysts currently see the stock settling into a valuation range between 120 and 150 dollars. Whether the price trends higher or lower will depend heavily on the specifics of the data presented later this year. Traders should remain cautious as the market continues to reprice the company based on these upcoming results.